GSK gains another cancer drug approval and unveils promising chemo data as it prepares for lung cancer approval

GSK received regulatory approval this week for one of its cancer medicines in an additional tumor indication, expanding the portfolio that has grown since the company re-entered oncology a decade ago.

The firm also presented early results from a worldwide trial of a next-generation chemotherapy, showing encouraging activity and safety signals that could position the drug as a future treatment option.

A separate GSK-licensed therapy was highlighted during a presidential session at a major oncology conference, drawing attention from the oncology community.

GSK expects another approval decision in the coming weeks for a lung cancer candidate, which would mark the company’s sixth cancer drug on the market if granted.